share_log

BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

BioNTech | 6-K: BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

BioNTech | 6-K:BioNTech在2023年ESMO大會上公佈晚期實體瘤中CAR-T細胞療法候選藥物BNT211的1/2期陽性數據更新
SEC announcement ·  2023/10/23 16:16
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息